Oligometastatic Prostate Cancer Treatment Outcomes from Five Chinese Centers

160 patients with oligometastatic prostate cancer were studied in a multicenter retrospective analysis spanning May 2010 to May 2023. The data compares perioperative and oncological outcomes between 80 patients receiving neoadjuvant hormonal therapy and 80 patients undergoing standard therapy, with a median postoperative follow-up of 52 months.

Use Cases

• Compare operative time and blood loss metrics between the neoadjuvant hormonal therapy and standard therapy groups.
• Analyze the relationship between biopsy Gleason score ≥8 and improved biochemical progression-free survival following neoadjuvant hormonal therapy.
• Model the positive surgical margin rate and pathological downstaging in T-stage as outcomes of different treatment protocols.
• Assess the frequency of subsequent treatments and ADT-related adverse events across patient cohorts.

Strengths

• Directly compares two treatment groups with 80 patients each, providing balanced cohort data.
• Includes long-term follow-up data with a median of 52 months post-operation.
• Multicenter design incorporates patient records from five Chinese medical centers.

Limitations

• The dataset is very small at 15.6 KB, indicating limited scope and likely summary-level data rather than raw patient records.
• As a retrospective study, it is subject to selection bias and confounding factors inherent to observational research.
• Patient population is exclusively from China, limiting generalizability to other geographic or demographic groups.

Provenance

Source

Yujie Dong via figshare.

Collection Method

Multicenter retrospective study.

Time Range

May 2010 to May 2023.

Freshness

Data collection ended in May 2023, with the record last updated in March 2026.

Geography

Five medical centers in China.